The Peptide NewsroomPeptide research, industry and supply-chain headlines

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Topic card: glp-1

An interview recorded at SupplySide Global by Nutritional Outlook has Filipa Quintela, associate director of global marketing at Kemin, setting out the three ingredient platforms the supplier expects to shape its product development. Her picks are positive aging, GLP-1 support, and gut health.

The named ingredients matter more than the trend labels. Slendesta is Kemin's satiety ingredient, and Gutopia is the gut platform holding BetaVia, described as a beta-glucan postbiotic from algae, and ButiShield, a short-chain fatty acid.

Lutein beyond the eye

Quintela says FloraGLO Lutein is backed by more than 100 clinical research publications, which is a genuinely large body of work for a single branded ingredient. Her own caveat is the important part: most of that research was done on eye health, and the move into cognitive health is where the science is going rather than where it already is.

She also wants the evidence extended across age groups, from pregnancy and early life through children and teenagers. That is a stated direction of travel from the company funding it, not a published result.

The GLP-1 adjacent market

The interesting commercial read here is that Kemin is not positioning Slendesta against GLP-1 drugs but alongside them. Quintela frames the opportunity as serving people who are on GLP-1, intending to start, or phasing out, and says the nutritional needs around that journey will keep shaping industry trends.

She expects 2027 to bring more maturity in the science around GLP-1 and nutrition, specifically identifying and addressing gaps. Which is a reasonable way of conceding that the gaps are currently unfilled.

Function over flora

On gut health, Quintela says there is no perfect gut and no perfect microbiome, and that Kemin believes in function over flora. The test she sets is whether an ingredient changes symptoms and quality of life rather than shifting a bacterial profile on a report.

That is a higher bar than most of this category sets for itself, and she names mechanistic evidence linked to function and symptoms as something to watch next year. She also flags gut health and women's health as a connection worth watching.

The gap nobody has closed

The hardest number in the interview is a consumption gap: Quintela puts American daily lutein intake at around 2 mg against what she says has been scientifically validated as optimal at 10 mg. After 30 years in the market, she calls that gap concerning, and suggests lutein could become the next vitamin.

No trial, publication or study name is attached to any of it, because this is a supplier outlining a roadmap at a trade show. What Kemin expects to prove by 2027 and what it has proven are different lists.

Source: RSS.app — Renewal bundle. Read the original.

Filed under: glp-1, skin-beauty, supply

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Karnataka's drug regulator canceled a Bengaluru "Peptide Party" on August 29 and questioned the organizers about ingredients, legality and health claims. The Indian Express reports the shutdown against a biohacking market Grand View Research valued at $1.21 billion in 2025.

FDA's Peptide Compounding Shakeup Blurs Drug and Supplement Lines, and Legitimate Brands Are Exposed

New Hope Network reports that FDA's shifting peptide compounding rules have left gray-market injectables like BPC-157 and TB-500 in regulatory limbo, while some supplement brands sell them under a Supplement Facts panel. Industry lawyers call that illegal, and legitimate peptide brands may pay the reputational bill.

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.